Surgery plays a major role as a first-line treatment of the different etiologies of Cushing's syndrome (CS) and bilateral adrenalectomy (BA) is extremely effective as a second line, so that there seems to be little room for medical treatment (MT). However, during the past years several drugs acting either on ACTH secretion or cortisol synthesis have been developed, so that MT of CS might be reassessed. After briefly analyzing the efficiency and tolerance of surgical and medical treatments of CS we try to distinguish consensual and controversial indications for MT. We believe the former include "pre-operative treatment" in rare patients in whom the severity of CS is likely to increase the risks of surgery; "inoperability" for rare patients who cannot be operated even when CS is controlled and "surgical failure or recurrence", mainly in patients Cushing's disease (CD) not in remission after TSS. Controversial indications include "unavailability of an expert surgeon", which we believe does not make sense when the cost of MT is taken into consideration. Finally in patients with the "surgical failure or recurrence" indication the balance between efficacy and side effects of MT should be balanced with the efficacy and side effects of BA.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711638 | PMC |
http://dx.doi.org/10.4183/aeb.2019.237 | DOI Listing |
Curr Hypertens Rep
January 2025
Department of Endocrinology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, 576104, India.
Purpose Of Review: Hypertension remains a major chronic disease morbidity across the world, even in the twenty-first century, affecting ≈40% of the global population, adversely impacting the healthcare budgets in managing the high incidence of cardiovascular disease (CVD) complications and mortality because of elevated blood pressure (BP). However, evaluation and management of endocrine hypertension are not optimal in clinical practice. With three unique clinical case scenarios, we update the evidence base for diagnostic evaluation and management of endocrine hypertension in this review to inform appropriate day-to-day clinical practice decisions.
View Article and Find Full Text PDFJ Clin Endocrinol Metab
January 2025
Endocrinology and Nutrition Department. Complejo Hospitalario Universitario de Albacete. Albacete (Spain). Hermanos Falcó, 37. 02006 Albacete (Spain).
J Clin Endocrinol Metab
January 2025
Department of Endocrinology, diabetes and nutrition, University Hospital of Bordeaux, 33604 Pessac, France.
Postgrad Med
January 2025
Department of Endocrinology, Ankara City Hospital, Ankara, Türkiye.
Purpose: Our study aimed to discern disparities in metabolic, hormonal profiles, and comorbidities among patients with pituitary Cushing (PC), adrenal Cushing (AC), and Mild autonomous cortisol secretion (MACS).
Methods: We conducted a retrospective analysis involving 76 patients diagnosed with PC ( = 26), AC ( = 21), and MACS ( = 29) at our clinic. We compared the groups' demographic data, clinical characteristics, biochemical profiles, hormonal analyses, and surgical interventions.
Aust Vet J
January 2025
Vetnostics, Macquarie Park, New South Wales, Australia.
Objective: Patient characteristics of Cushing's syndrome differ between countries and have not been assessed in the Australian dog population. This study describes signalment and distribution of adrenocorticotropic hormone (ACTH)-dependent hypercortisolism (ADH) and ACTH-independent hypercortisolism (AIH) in Australian dogs.
Animals: Two-hundred client-owned dogs that had endogenous ACTH concentrations measured by radioimmunoassay.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!